Clinical influence of switching companion diagnostic tests for EGFR‐TKs from Therascreen to Cobas v2.

MLA

Uchibori, Ken, et al. “Clinical Influence of Switching Companion Diagnostic Tests for EGFR‐TKs from Therascreen to Cobas V2.” Thoracic Cancer, vol. 12, no. 6, Mar. 2021, pp. 906–13. EBSCOhost, https://doi.org/10.1111/1759-7714.13797.

APA

Uchibori, K., Takano, N., Manabe, R., Tsugitomi, R., Ogusu, S., Tozuka, T., Sakamoto, H., Yoshida, H., Amino, Y., Ariyasu, R., Kitazono, S., Yanagitani, N., & Nishio, M. (2021). Clinical influence of switching companion diagnostic tests for EGFR‐TKs from Therascreen to Cobas v2. Thoracic Cancer, 12(6), 906–913. https://doi.org/10.1111/1759-7714.13797

Chicago

Uchibori, Ken, Natsuki Takano, Ryo Manabe, Ryosuke Tsugitomi, Shinsuke Ogusu, Takehiro Tozuka, Hiroaki Sakamoto, et al. 2021. “Clinical Influence of Switching Companion Diagnostic Tests for EGFR‐TKs from Therascreen to Cobas V2.” Thoracic Cancer 12 (6): 906–13. doi:10.1111/1759-7714.13797.